Reaction sensing in living cells

Information

  • Patent Application
  • 20100227334
  • Publication Number
    20100227334
  • Date Filed
    September 15, 2006
    18 years ago
  • Date Published
    September 09, 2010
    14 years ago
Abstract
Chemical reactions occurring within a living cell are measured in a manner that does not affect the viability of the cell or the reaction under study. In one embodiment, one or more sensors are introduced into the cell and/or covalently associated with the exterior cell membrane. The sensor(s) emit an observable signal indicating a value of a parameter associated with the chemical reaction, e.g., the concentration of a reaction product. Because cell viability is not compromised, the cell may be stimulated (e.g., by subjection to an agonist or antagonist, a pathogen, a pharmaceutical compound, or a potential toxin) so as to affect the reaction under study.
Description
FIELD OF THE INVENTION

The invention relates to monitoring chemical reactions occurring within living cells, and more particularly to methods and apparatus for measuring such reactions without compromising the viability of the cells.


BACKGROUND OF THE INVENTION

Numerous techniques exist for monitoring the extent and time profile of a chemical reaction of interest occurring within a living cell. Many such techniques are indirect, involving an assay for reaction products outside the cell that reflect the progress of reaction(s) taking place in the cytoplasm. A disadvantage of such assays is their vulnerability to influence by the spurious presence of reaction products in the cell's environment that do not, in fact, emanate from the cell.


Intracellular techniques have also been developed; these include, for example, genetically engineering cells to fluoresce in the presence of a compound of interest, radioactive binding assays, and colorimetric assays. These techniques, however, require potentially destructive modification or invasion of the cell.


Intracellular and extracellular assays are often employed to track enzymatic activity by measuring the amount of reaction product through the use of coupling. Enzymatic coupling is a complicated approach that links a non-quantifiable enzymatic reaction of interest with an optically measurable (by means of a spectrophotometer) enzymatic reaction that will interact with the products of the enzymatic reaction of interest. Once again, conventional approaches suffer from a number of deficiencies. For example, coupled reactions necessarily involve at least one chemical reaction unrelated (“coupled”) to the enzymatic activity of interest, imparting potential sources of error. Enzymatic reactions require carefully controlled reaction conditions (appropriate temperatures, pHs, salt concentrations, etc.) and, as a result, monitoring efforts can be affected by rapid environmental changes or degradation of reagents, e.g., components of the enzymatic reactions (especially the enzyme itself).


Accordingly, there is a need for apparatus and methods that quickly, directly and accurately measure a product of interest.


SUMMARY OF THE INVENTION

The present invention addresses the shortcomings of the prior art by measuring chemical reactions occurring within a living cell in a manner that does not significantly affect the viability of the cell or the reaction under study. By “significantly” is meant, with respect to individual cells, that these are not killed; with respect to a population of cells, that at least the majority remains viable; and with respect to a reaction, that the variable under study is not affected beyond a predetermined threshold of precision. For example, if it is necessary to monitor the concentration of an ion to within 0.1 mole/L, the reaction is not significantly affected if the ion concentration is not shifted more than ±0.05 mole/L.


In one embodiment, one or more sensors are introduced into the cell and/or covalently associated with the exterior cell membrane. The sensor(s) produce an observable signal indicating a value of a parameter associated with the chemical reaction, e.g., the concentration of a reaction product. Because cell viability is not compromised, the cell may be stimulated (e.g., by subjection to an agonist or antagonist, a pathogen, a pharmaceutical compound, or a potential toxin) so as to affect the reaction under study. By “observable” is meant visible or measurable using instrumentation.


In some embodiments, the sensor is used to monitor the activity of an ion channel through the cell membrane. In such cases, the sensor may be introduced within the cell, may be attached to the exterior cell membrane, or both. For example, the external sensor may be attached to the cell membrane proximate to an ion channel of the cell, e.g., via an antibody specific to the ion channel (which typically comprises a protein). The sensor may be an ion sensor, and sensors internal and external to the cell may monitor different ions.


In some embodiments, the sensor comprises an ion-selective optode. The reaction may produce an ionic product that is sequestered by the optode, or instead, the reaction may produce a non-ionic product that is ionized to facilitate monitoring using the optode. In this way, the invention can be used in numerous pharmaceutical applications involving small molecules.


In some embodiments, the optode comprises an ion-selective ionophore, a source of triggering ions, and a signaling agent responsive to the triggering ions. Typically the ionophore is selective for the ionic reaction product, and upon binding of a reaction-product ion, a triggering ion is released to interact with the signaling agent and thereby produce the signal. The strength of the signal may be indicative of the concentration of the triggering ion, which itself reflects the concentration of the ionic reaction product. Different sensors, each responsive to different ions and producing differentiable signals, can be used depending on the reaction(s) being monitored. Furthermore, the signal may be produced directly by the triggering ions, or may be produced indirectly (e.g., the triggering ions may initiate a reaction cascade that results in an observable signal).


In preferred embodiments, the signal is optical in nature, e.g., involving fluorescence or absorbence. The optical signal may be monitored using, for example, a spectrometer, a fluorometer, or a detector for measuring absorbance. But the signal may alternatively be non-visible or may involve other forms of electromagnetic radiation.


The foregoing and other features and advantages of the present invention will be made more apparent from the description, drawings, and claims that follow.





BRIEF DESCRIPTION OF DRAWINGS

The advantages of the invention may be better understood by referring to the following drawings taken in conjunction with the accompanying description in which:



FIG. 1 is a schematic diagram of a cell assay system according to an illustrative embodiment of the invention.



FIGS. 2A-2D are cross-sections of various optical ion sensor arrangements suitable for use in various implementations of the cell assay system of FIG. 1.



FIG. 3 presents another embodiment of a microfluidic device in accord with the present invention.



FIG. 4 depicts the embodiment of FIG. 5 with fluorescence from the channels imaged.



FIG. 5 presents a hypothetical response of yeast cells to a stimulus (Haloperidol).



FIG. 6 presents data from an exemplary study using a sensor in accord with the present invention to monitor the reaction of yeast cells to Haloperidol. Sodium is shown on the left and potassium on the right.



FIG. 7 illustrates an embodiment of the present invention used as an ammonia sensor.



FIG. 8 depicts the calibration curve for the embodiment of FIG. 7.



FIG. 9 presents the data from real-time monitoring of Tgase reactions using sensors in accord with one embodiment of the present invention, using 12.5 mM substrate (Z-Gln-Gly) and 1.00, 0.20, and 0.02 units/ml Transglutaminase at 30° C. Each curve represents the average reading from 5-8 reactions.



FIG. 10 presents the data from real-time monitoring of TGase reactions using sensors in accord with another embodiment of the present invention, having various substrate (Z-Gln-Gly) concentrations and 0.4 units/ml Transglutaminase at 30° C. Each curve represents the average reading from 3 reactions.


In the drawings, like reference characters generally refer to corresponding parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed on the principles and concepts of the invention.





DETAILED DESCRIPTION OF THE INVENTION

In brief overview, embodiments of the present invention provide systems, methods and devices for measuring cellular biomarkers. In exemplary embodiments, optically active polymer sensors are placed inside or outside a cell. Changes in fluorescence or absorbance indicate the ion concentrations and fluxes from the cell. The overall change in fluorescence or absorbance in response to a compound of interest provides a “fingerprint” (e.g., a spectrum) for that compound.



FIG. 1 is a schematic diagram of a cell assay system 100 according to an illustrative embodiment of the invention. The cell assay system 100 includes an optical ion sensor support 102, a biological sample holder 104, an excitation light source 106, a light sensor 108, and a computing device 111.


The optical ion sensor support 102 supports an optical ion sensor 112 for positioning in the biological sample holder 104. In various implementations, the optical ion sensor 112 is adhered to the optical ion sensor support 102 by deposition in a solution of optical ion sensor matrices dissolved or dispersed in a solvent, such as in a polar organic solvent like tetrahydrofuran (THF). In such implementations, the sensor support 102 is preferably formed from a material resistant to the solvent. Materials resistant to THF include, without limitation, 304 stainless steel; 316 stainless steel; acetal polymer (marketed as DELRIN by E. I. du Pont de Nemours and Company); bronze; carbon graphite; carbon steel; ceramic Al2O3; a perfluoroelastomer compound, such as CHEMRAZ marketed by Greene, Tweed; epoxy; HOSTELRY Calloy (marketed by Haynes International, Inc.); KALES elastomer (marketed by DuPont Performance Elastomers); polychlorotrifluoroethylene; NYLON (marketed by E. I. du Pont de Nemours and Company); polyetherether ketone (PEEK); polyphenylene sulfide; and PTFE.


The optical ion sensor 112 includes a film having a suspension of optical ion sensor matrices. The optical ion sensor matrices, in general, include an ionophore, an additive, and a chromionophore suspended in a polymer phase, for example, of polyvinyl chloride (PVC). The polymer phase also includes a plasticizer such as dioctyl sebacate (DOS). An ionophore is a substance that allows targeted ions to move across or into a membrane. Preferably the ionophore is selected to be lipid-soluble. In addition, the ionophore is preferably an electrically neutral compound that forms a complex with a target ion. The ionophore is optically inactive in the visible spectrum and does not change absorbance or fluorescence depending on its state of complexation.


A chromoionophore is an ionophore that changes its optical properties in the visible spectrum depending on the state of complexation. Chromoionophores are preferably proton-sensitive dyes that change absorbance (and fluorescence in many cases) depending on its degree of hydrogen complexation (protonation). The chromionophores are preferably highly lipophilic to prevent them from leaching out of the optical ion-sensor matrix. Suitable chromionophores include Chromoionophore II and Chromionophore III. Chromionophore II exhibits light absorbance peaks at 520 nm and 660 nm and a fluorescent emission peak at 660 nm. Chromionophore III has light absorbance peaks at 500 nm and 650 nm and fluorescent emission peaks at 570 nm and 670 nm.


It should be stressed that the triggering ion released by the ionophore may be observed directly, as discussed above, or indirectly. For example, the intensity of the fluorescence signal may be a trigger for an event cascade within the cell. A large calcium current may cause the sensor to fluoresce brightly, for instance, whereas low calcium does not. The fluorescence may in turn excite a secondary dye in the particle that easily generates reactive oxygen species (ROS). The ROS would then attack the cell, effectively stimulating necrosis (cell death). Alternatively, instead of a secondary component within the particle, another particle may be added. This additional particle may comprise a photo-degradable polymer. When the primary sensory fluoresces, the emitted light will break apart the secondary particle, releasing its contents. The contents may, for example, be a drug that is therapeutic or cancer-fighting (stimulating apoptosis).


For optical ion sensors targeting cations, the additive can be any inert lipophilic component that has a negative charge associated with it. For optical ion sensors targeting anions, the additive is positively charged. The purpose of the additive is to embed charge sites within the polymer phase, and to help enforce charge neutrality within the optical ion sensor 112. The additive allows the polymer phase to carry an equal amount of charged particles as additive. The concentration ratio of additive to chromoionophore is preferably 1:1, thereby allowing the chromoionphore to become completely protonated or de-protonated. One suitable additive for optical ion sensors targeting negative ions is potassium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (KTFPB). The lipophilic, anionic component TFPB molecules are retained by the polymer phase, and the potassium ions are either complexed by the ionophore or expelled into the sample solution through diffusion. In one particular implementation, the optical ion sensor film is composed of a suspension produced from about 60 mg of DOS, 30 mg of PVC, and up to about 5 mg of additive, ionophore, and chromionophore.


Once the above components are dissolved into the polymer phase to form the optical ion sensor 112 and are exposed to a sample solution, the optical ion sensor 112 becomes active. It now continuously extracts or expels analyte cations (a system can work with anions as well using ion coextraction) depending on ion activity in the sample solution. With a 1:1 additive-chromoionophore ratio, and with zero target ions present in the sample solution, the optical ion sensor 112 remains completely protonated to achieve charge neutrality. As the target ion concentration increases, the ionophores in the optical ion sensor 112 extract the target ions into the optical ion sensor 112. To maintain charge neutrality of the optical ion sensor 112, hydrogen (hydronium) ions are stripped from the chromoionophores in the optical ion sensor 112 and expelled into the sample solution. The expelling of hydrogen ions alters the pH of the optical ion sensor 112, thereby altering its fluorescent properties. To detect analyte anions (for example, chloride or nitrite ions), the optical ion sensor uses ion-coextraction, as opposed to proton expulsion. To detect neutral analytes, an additional agent known to interact with the target analyte to yield an ion is added to the biological sample holder 104. An ionophore is then selected to detect the resultant ion.


The following is a non-limiting, illustrative list of target ion/ionophore pairings suitable for use in the optical ion sensors: potassium/Potassium Ionophore III (BME-44), sodium/Sodium Ionophore IV, sodium/Sodium Ionophore V, sodium/Sodium Ionophore VI, calcium/Calcium Ionophore III, and calcium/Calcium ionophore IV. For target anions, illustrative target ion/ionophore pairings include chloride/Chloride Ionophore III and nitrite/Nitrite Ionophore I.


The film of the optical ion sensor can be produced in various ways. In one implementation, as described above, a predetermined amount of the optical ion sensor suspension (i.e., the combined polymer phase, ionophore, additive, and chromionophore) is dissolved in a solvent, such as THF. The solution is then deposited, sprayed, or spun onto a surface. The solvent evaporates, leaving the optical ion sensor film on the surface.


In another implementation, the film is formed from a deposition of optical ion sensor microspheres. To produce the microspheres, an optical ion sensor emulsion is formed by injecting an optical ion sensor suspension dissolved in THF (e.g., 16 mL THF/100 mg PVC) into a pH buffered solution. The optical ion sensor suspension includes approximately 60 mg of DOS, 30 mg of PVC, and up to approximately 5 mg of chromionophore, additive, and ionophore. The emulsion is then submerged in a sonicating water bath. Typically, 50 μL of the optical ion sensor suspension/THF solution is injected into 1,000-1,500 μL of buffered solution. The resulting emulsion contains a mixture of spherical optical ion sensor particles ranging in size from 200 nm to 20 μm. The resulting emulsion can be spun, sprayed, or evaporated onto any surface to create a porous optical ion sensor membrane. Films formed from microspheres tend to expose a greater surface area of optical ion sensor to a given sample, yielding improved performance characteristics.


The biological sample holder 104 holds a biological sample for analysis by the cell assay system 100. The biological sample can include cells adhered to the walls of the biological sample holder 104, for example, in a monolayer, or cells suspended in a liquid buffer. The biological sample holder 104 is preferably transparent, or at least includes a transparent region through which the optical ion sensor 112 can be excited and through which the results of such excitement can be monitored.


The optical ion sensor 112 is illuminated with a light source 106 to excite the chromionophores suspended therein. The light source preferably can be tuned to generate one or more predetermined wavelengths of light, desirably in the visible portion of the electromagnetic spectrum, that are selected to excite the particular chromionophore used in the optical ion sensor 112. Alternatively, the light source may generate a wide spectrum light. In one implementation, the light source 106 is coupled to the optical ion sensor support 102.


The fluorescence of the optical ion sensor 112 is detected by a light sensor 108. The light sensor 108 may include a charge-coupled device, a fluorometer, a photomultiplier tube, or other suitable device for measuring fluorescence. In one implementation, a spectrophotofluorometer is used to satisfy the roles of the light source 106 and the light sensor 108. The light sensor 108 may also be coupled to the optical ion sensor support 102.


The optical ion sensor support 102 includes an agent introduction means 118. The agent introduction means 118 can include a pipette or an electro-mechanical dispenser device, such as a solenoid or electrostatically driven plunger or syringe.


The computing device 111 controls the various components of the cell assay system 100. The computing device 111 may be a single computing device or multiple computing devices providing the various functionalities used to control the cell assay system. These functionalities are provided by an excitation control module 126, an agent introduction module 130, and an analysis module 134. The excitation control module 126 controls the light source 108 to emit one or wavelengths of excitation light. The agent introduction module 130 controls the introduction of an agent into the biological sample holder 104 via an agent introduction means 118. The analysis module 134 analyzes the output of the light sensor 108, e.g., before and after an agent is introduced into the biological sample holder 104 to determine the effect of the agent on the cells in the biological sample holder 104. The analysis module 134 may also control the other modules in the computing device, i.e., the excitation control module 126 and the agent introduction module 130, to coordinate an assay protocol. The computing device 111 and/or devices may also include various user interface components, such as a keyboard, mouse, trackball, printer, and display.


A module may be implemented as a hardware circuit comprising custom VLSI circuits or gate arrays, off-the-shelf semiconductors such as logic chips, transistors, or other discrete components. A module may also be implemented in programmable hardware devices such as field programmable gate arrays, programmable array logic, programmable logic devices or the like.


Modules may also be implemented in software for execution by various types of processors. An identified module of executable code may, for instance, comprise one or more physical or logical blocks of computer instructions which may, for instance, be organized as an object, procedure, or function. Nevertheless, the executables of an identified module need not be physically located together, but may comprise disparate instructions stored in different locations which, when joined logically together, comprise the module and achieve the stated purpose for the module. A module of executable code may be a single instruction, or many instructions, and may even be distributed over several different code segments, among different programs, and across several memory devices.


The various modules are in communication with the various devices they control or obtain data from. They maybe connected over a local area network, wirelessly, over a bus, or over typical cables known in the art of computer interfaces for connecting computing devices with peripherals.



FIGS. 2A-2D depict various optical ion sensor arrangements suitable for use in various implementations of the cell assay system 100 of FIG. 1. FIG. 2A shows a first optical ion sensor arrangement that includes an optical ion sensor support 202 and a biological sample holder 204. The biological sample holder 204 includes a monolayer of cells 206 adhered to the biological sample holder 204. Alternatively, the biological sample holder 204 holds cells suspended in a buffer. The optical ion sensor support 202 and biological sample holder 204 correspond to the optical ion sensor support 102 and biological sample holder 104 of FIG. 1. An optical ion sensor film 210 is coupled to the distal end of the optical ion sensor support 202.



FIG. 2B illustrates an alternative optical ion sensor arrangement 250, which includes a biological sample holder 254 having therein a monolayer of cells 256 adhered to the surfaces of the biological sample holder 254, or cells suspended in a buffer. Instead of including an optical ion sensor film adhered to a support, the optical ion sensor arrangement 250 relies upon optical ion sensor particles 258 introduced into the cells 256 adhered to the biological sample holder 254.


To introduce optical ion sensors into cells, the optical ion sensors are produced as particles 258. The optical ion sensor particles 258 are fabricated in a fashion similar to the optical ion sensor film 112 described above. One such particle 258, the optical ion sensor nanosphere, is produced according to the following procedure. First a optical ion sensor suspension is dissolved in 500 μl of THF. The suspension preferably includes 60 mg of DOS, 30 mg of PVC and up to about 5 mg of chromoionophore, ionophore, and additive to form an optode solution. Then, 500 μl of CH2Cl2 is added to bring the total volume to 1 ml. Next, a PEG-lipid solution is prepared by dissolving a PEG-lipid (such as DSPE-PEG 550 or DSPE-PEG (2000) Folate) in 5 ml of a water, salt and buffer solution. A TAT peptide can be added to the PEG-lipid via an amine linkage to aid the resulting nanospheres in entering cells. Alternatively, it is possible to utilize a molecule that is not a PEG, e.g., a ganglioside attached to ceramide.


The nanospheres are formed by adding 100 μl of optode solution dropwise to 5 ml of the PEG-lipid solution while the solution is being sonicated by a probe tip sonicator. Additional sonication is performed for approximately 2-3 minutes. The resultant nanosphere solution is sprayed through a nitrogen-feed air gun into a beaker several times to remove excess solvent. If desired, the nanosphere solution is pushed through a 0.22 μm filter to remove the larger spheres.


The optical ion sensor particles 258 are introduced into the cells 256 in any suitable manner. In one method, the particles 258 are introduced into a buffer liquid deposited in the biological sample holder 254. A voltage source then generates a voltage sufficiently strong to electroporate the cells 256, thereby allowing the optical ion sensor particles 258 to enter directly into the cells. In another approach, the surfaces of the optical ion sensor particles 258 are first coated with a substance, for example transferrin or folate, which assist the particles 258 in crossing through cell membranes. The optical ion sensor particles 258 are introduced into a buffer in the biological sample holder 254, and the cells 256 bring the particles 258 into their interior in vesicles via endocytosis, pinocytosis, or phagocytosis, or similar biological processes. The substance applied to the optical ion sensor particles 258 breaks down the vesicle membrane, releasing the optical ion sensor particles 258 into the cell cytoplasm. In still other approaches, the particles 258 may be introduced into cells 256 using a glass needle or through ballistic bombardment.


In some embodiments, the sensor is attached to the exterior of a cell rather than introduced into the interior. If, for example, the activity of an ion channel is to be studied, the sensor may be attached to the cell proximate to the ion channel. This may be accomplished, for example, by raising antibodies against the ion-channel protein and, using conventional chemistries, covalently linking one or more such antibodies to a sensor particle as described above. The antibody-studded particles are released into a cell suspension and preferentially bind to the ion channel. This approach can be used to link ion-specific sensors to any feature on the exterior of the cell membrane to which antibodies can be raised. Alternatively, the sensors may be attached to the cell membrane by other suitable coupling chemistries, e.g., biotin-(strept)avidin complexing or polysaccharide binding. See the thesis “High Throughput Optical Sensor Arrays for Drug Screening” by Daniel I. Harjes (2006), available from the Massachusetts Institute of Technology and incorporated herein by reference.



FIG. 2C illustrates a second alternative optical ion sensor arrangement 270 that includes an optical ion sensor support 272 and a biological sample holder 274. An optical ion sensor film 276 is coupled to the distal end of the optical ion sensor support 272. A cell monolayer 278 adheres to the surfaces of the biological sample holder 274. Alternatively, cells are suspended in a buffer. In addition, optical ion sensor particles 280 are introduced into the cells of the cell monolayer 278. Preferably the chromionophores used in the optical ion sensor film 276 differ from the chromionophores used in the optical ion sensor particles 280. In particular, the different chromionophores desirably have distinguishable fluorescence characteristics such that an analysis module analyzing the output of a light sensor monitoring the optical ion sensor arrangement 270 can differentiate between the output of the optical ion sensor film 272 and the optical ion sensor particles 280. As a result, the analysis module can differentiate between intracellular target ion concentration and extracellular target ion concentration. In addition, the optical ion sensor film 272 may include ionophores different from those included in the optical ion sensor particles 280. Thus, the optical ion sensor arrangement 270 can monitor the concentrations of two different target ions.



FIG. 2D illustrates a third alternative optical ion sensor arrangement 290 that includes an electrode support 292 and a biological sample holder 294. The biological sample holder 294, in addition to a cell monolayer 296 or cells suspended in a buffer, includes a removable optical ion sensor film 298. The removable optical ion sensor film 298, for example, can be a glass cover slip or other transparent surface coated with an optical ion sensor film.


In still another embodiment, the optical ion sensor film is coated onto the inner surface of the biological sample holder. And in another approach, to accommodate the 96-well plate format often used in assays, one embodiment of the present invention utilizes round glass coverslips coated with the ion-exchange optode material along with the cells to be monitored. In this embodiment, each well contains a single sensor type to track a specific species of interest; the various sensor types may differ only in the ionophore employed and utilize the same or similar chromoionophores. The compound of interest is then added directly to the well. The 96-well plate is then placed in a standard plate-reader type fluorometer, and the fluorescence intensity is monitored with time.


In a typical implementation, a plurality of biological sample holders holding biological samples is provided. Biological samples introduced into the holders may include cells suspended in a buffer solution, but alternatively, cells may be adhered to the walls of the biological sample holders. Next, optical ion sensors are introduced into the biological sample holders as shown in FIGS. 2A and 2C, and/or are introduced into the cells themselves. Alternatively, the optical ion sensors can coat the walls of the biological sample holders. As described above, optical ion sensor particles can be introduced either by electroporating the cells via electrodes positioned in the biological sample holders or by the chemistry applied to the optical ion sensor particles breaching vesicle membranes within the cells. Similarly, the optical ion sensor sensors can be introduced into the cells using pico-injection, bead loading, a gene gun, or through liposomal delivery techniques known in the art. As described above, the optical ion sensors include at least one ionophore for selectively binding a predetermined ion. In some embodiments, this results in altering the pH of the optical ion sensor and a pH-sensitive chromionophore for optically indicating the concentration of the ion in a fluid surrounding the optical ion sensor. Ion concentration, in other words, is indicated by the pH of the optical ion sensor and the resulting fluorescence of the chromionophore.


An agent, such as a therapeutic, toxin, biological macromolecule (such as a nucleic acid, an antibody, a protein or portion thereof, e.g., a peptide), small molecule (of 2000 amu or less, 1000 amu or less or 500 amu or less), protein, virus, bacteria, chemical compound, mixture of chemical compounds, or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues, or other biologically active agent may be introduced into one or more of the biological sample holders. In one particular implementation using an array of biological sample holders, no agent is introduced into a first row of biological sample holders to preserve a control. A first agent is introduced into a second row of biological sample holders. Additional agents are added to additional rows of the array of biological sample holders.


The fluorescence of the optical ion sensors introduced into the biological sample holders is monitored. The monitoring preferably begins prior to introduction of the agents and continues thereafter. Changes in ion concentration resulting from the introduced agents are then determined. By comparing the changes in ion concentration after adding an agent, one can determine the effect of the agent on the cells being tested.



FIGS. 3 and 4 present another embodiment 300 of a sensor in accord with the present invention. The sensor comprises a well 310 and micro-channels, indicated generally at 315, branching successively therefrom. The cells are placed in the well 310, sensor materials with different specificities line each of the channels 315, and a solution is flowed from the well 310 through the channels 315. When the fluorescence from the channels 315 is imaged, the pattern formed by changes in intensity may be visualized as an optical barcode, as depicted in FIG. 4, indicating the presence or absence of the various sensed materials in the solution.


Exemplary Applications: HERG Compatibility

The sensors of the present invention are suited to many different types of assays, or for the detection of compounds. In one exemplary application, a model cell system is used to screen for HERG compatibility. HERG (human ether-a-go-go) channels are implicated in the abnormal heart rhythms associated with Long QT Syndrome. It is believed that many compounds can block these channels and cause prolongation of the beat cycle of the heart. This abnormal rhythm can cause arrhythmia and can even lead to death. Accordingly, it is important that all drugs, regardless of therapeutic target, be screened for HERG compatibility.


With reference to FIG. 5, the model cell system to be used is Saccharomyces cerevisiae, as it contains a native ERG2 gene which is similar to the human HERG. It has been shown that known HERG inhibitors also interfere with the function of ERG2 in yeast. Much is known genetically about yeast, and gene knock-outs are commercially available, allowing for the screening of two types of yeast: the wild type (WT) containing the ERG2, and one mutated to knock-out the ERG2 gene.


With reference to FIG. 6, using both potassium and sodium sensors according to the present invention with both yeasts stimulated with a known HERG inhibitor, Haloperidol (an anti-psychotic drug), a change is observed in sodium and potassium upon stimulation of the cells with Haloperidol. In the ERG2 knock-out, there is no response. This example utilizes two cell types and two types of sensors, providing four different data signals, and the approach can be extended to an arbitrary number of sensors and cell types. Similarly, tissue can be used instead of culture.


Exemplary Applications: Ammonia Screening

As explained above, pH changes can be used to render neutral reaction products of interest measurable using an ion-exchange optode. For a sensor developed to monitor ammonia production in biological reactions (e.g., involving an enzyme such as transglutaminase (TGase)), for example, a low pH ionizes ammonia to ammonium, which may be extracted by a nonactin ionophore. This approach greatly expands the range of measurable species.


With reference to FIG. 7, an ammonia sensor is made by coating a 5 mm glass disk with an ammonium/ammonia-selective cocktail containing PVC, plasticizer, THF, potassium tetrakis (p-chlorophenyl)borate (KTpClPB), Chromoionophore III, and nonactin. A second, thin layer of 5% TEFLON is optionally applied to the coated disk to protect the ammonium cocktail from the high-salt environment required for the enzymatic reaction. These disks are placed in the bottom of individual wells in 96-well plates and the enzymatic reaction is set up to occur in the well, submerging the disks. Real-time monitoring of the reaction (through measuring the change in fluorescence of the optical sensor) is performed. Although these optodes are fairly large and coated with TEFLON, their response time is still approximately 2 minutes.


To utilize data monitoring in order to track the change in fluorescence of the sensors in the presence of an enzymatic reaction, a calibration curve of fluorescence readings of known concentrations of the ion of interest is first constructed. With reference to FIG. 8, this curve is typically sigmoidal, with the linear portion of the curve coinciding with the sensor's range of greatest accuracy. As depicted, in the case of a TGase reaction, the ammonia concentration currently susceptible to measurement is 10−4-10−3 M, although sensitivity is anticipated in the range of 10−5-10−3 M.



FIGS. 9 and 10 present the results of monitoring of the TGase reaction. Varying enzyme and substrate concentrations of the TGase reaction demonstrate the operation of the optical sensors. In particular, these results show that the higher the enzyme concentration or the higher the substrate concentration in the reaction, the faster ammonia is produced.


Further Applications

As discussed above, various embodiments of the present invention may be constructed to directly detect the presence of particular ions. As illustrated in Table 1 below, it is known to the art that certain diseases affect particular ion channels in a cell. Accordingly, assays for those ions utilizing the present invention may furnish a diagnostic tool to determine the presence of particular diseases. Accordingly, the scope of the present invention should be understood to also include the application of the heretofore-described subject matter to measure the ions set forth in the following tables, as well as their application to diagnose the presence of the associated diseases also appearing in the following tables.
















Channel
Gene
Channel-forming unit/ligand
OMIM
Disease



















Cation channels:






CHRNA1/ACHRA
CHRNAI
α, ACh
100690
Myasthenia congenita


CHRNA4
CHRNA4
α, ACh
118504
Autosomal dominant nocturnal frontal lobe epilepsy


CHRNB2
CHRNB2
β, ACh
118507
Autosomal dominant nocturnal frontal lobe epilepsy


Polycystin-2
PKD2
α
173910
Autosomal dominant polycystic kidney disease (ADPKD)


CNGA3
CNGA3
α, cGMP
60053
Achromatopsia 2 (color blindness)


CNGB1
CNGB1
β, cGMP
600724
Autosomal recessive retinitis pigmentosa


CNGB3
CNGB3
β, cGMP
605080
Achromatopsia 3


Sodium channels:


Na.1.1
SCN1A
α
182389
Generalized epilepsy with febrile seizures (GEFS+)


Na.1.2
SCN2A
α
182390
Generalized epilepsy with febrile and afebrile seizures)


Na.1.4
SCN4A
α
603967
Paramyotonia congenital, potassium aggressive myotonia,






hyperkalemic periodic paralysis


Na.1.5
SCN5a
α
600163
Long-QT syndrome, progressive familial heart block type 1,






Brugada syndrome (idiopathic ventricular arrhythmia)


SCNIB
SCN1B
β
600235
Generalized epilepsy with febrile seizures (GEFS+)


ENACα
SCNNIA
α
600228
Pseudohypoaldosteronism type 1 (PHA1)


ENaCβ
SCNN1B
β
600760
PHA1, Liddle syndrome (dominant hypertension


ENaCγ
SCNN1G
γ
600761
PHA1, Liddle syndrome


Potassium channels:


K, 1.1.
KCNA1
α
176260
Episodic ataxia with myokymia


KCNQI/K, LQT1
KCNQ1
α
192500
Autosomal dominant long-QT syndrome (Romano-Ward)






Autosomal recessive long-QT syndrome with deafness (Jervell-






Lange-Nielsen)


KCNQ2
KCNQ2
α
602235
BFNC (epilepsy), also with myokymia


KCNQ3
KCNQ3
α
602232
BFNC (epilepsy)


KCNO4
KCNQ4
α
603537
DFNA2 (dominant hearing loss)


HERG/KCNH2
KCNH2
α
152427
Long-QT syndrome


Kir1.1/ROMK
KCNJ1
α
600359
Bartter syndrome (renal salt loss, hypokalemic alkalosis)


Kir2.1/IRK/KCNJ2
KCNJ2
α
600681
Long-QT syndrome with dysmorphic features (Andersen






syndrome)


Kir6.2/KATATPATP
KCNJ11
α
600937
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI)


SURI
SURI
β
600509
PHHI


KCNE1/Mink/ISK
KCNE1
β
176261
Autosomal dominant long-QT syndrome (Romano-Ward)






Autosomal recessive long-QT syndrome with deafness (Jervell-






Lange-Nielson)


KCNE2/MiRP1
KCNE2
β
603796
Long-QT syndrome


KCNE3/MiRP2
KCNE3
β
604433
Periodic paralysis


Calcium channels:


Ca, 1.1
CACNA1S
α
114208
Hypokalemic periodic paralysis, malignant hyperthermia


Ca, 1.4
CACNA1F
α
300110
X-linked congenital stationary night blindness


Ca, 2.1
CACNA1A
α
601011
Familial hemiplegic migraine, episodic staxia, spinocerebella






ataxia type 6


RyRI
RYR1
α
180901
Malignant hyperthermia, central core disease


RyR2
RYR2
α
180902
Catecholaminergic polymorphic ventricular tachycardia,






arrhythmogenic right ventricular dysplasia type 2


Chloride channels:


CFTR
ABCC7
α
602421
Cystic fibrosis, congenital bilateral asplasia of vas deference


CIC-1
CLCN1
α
118425
Autosomal recessive (Becker) or dominant (Thomsen myotonia


CIC-5
CLCN5
α
300008
Dent's disease (X-linked proteinuria and kidney stones)


CIC-7
CLCN7
α
602727
Osteopetrosis (recessive or dominant)


CIC-Kb
CLCNKB
α
602023
Bartter syndrome type III


Barttin
BSND
β
606412
Bartter syndrome type IV (associated with sensorineural






deafness)


GLRA1
GLRA1
α, glycine
138491
Hyperekplexin (startle desease)


GABAα1
GABRA1
α GABA
137160
Juvenile myoclonus epilepsy


GABAγ2
GABRG2
γ, GABA
137164
Epilepsy


Gap junction channels:


Cx26
GJB2

121011
DFNB3 (autosomal dominant hearing loss)






DFNB1 (autosomal recessive hearing loss)


Cx30
GJB4

605425
DFNA3


Cx31
GJB3

603324
DFNA2


Cx32
GJB1

304040
CMTX (X-linked Charcot-Mari-Tooth neuropathy)


AChR α7



Inflammation


ClC7



Osteoporosis


Ether-a-go-go (eag, erg, elk)



Cancer


Gardos channel



Sickle cell anemia


P2X7



Immune disorders


TRPC6



Asthma, COPD


TRPM1



Melanoma


TRPM2



Asthma


TRPM4



Immune disorders


TRPM7



Stroke


TRPM8



Prostate cancer


TRPV1



Urinary incontinence, pain





The third column classifies channel proteins into α, β, and γ subunits, where α subunits are always directly involved in pore formation, Several β subunits are only accessory (i.e., do not form pores), as is the case, for example, with SCN1B and barttin. Others (e.g. of ENaC and GABA receptors) participate in pore formation. For ligand-gated channels, the ligand is given. Note that GABA and glycine act from the extracellular side, whereas cGMP is an intracellular messenger.




















Gene
Accession ID
Gene Locus

Tissue Expression










Sodium Channel Type/Disease



SCN1A
GDB: 118870
2q24
SCN1, vg type 1, α-subunit (280 KDa)
Brain



S71446


SCN1B
GDB: 127281
19q13.1
Hs.89634, vg type 1 β1 subunit
Brain, heart, skeletal



U12188-12104

(38 KDa)
muscle



L16242, L10338


SCN2A1
GDB: 120367
2q23
SCN2A, HBSCI, vg type II, α1-
Brain, peripheral nerve





subunit (280(KDa)


SCN2A2
CDB: 133727
2q23-24.1
HBSCH, vg type II, α2-subunit vg
Brain





type II, β2-subunit (33 KDa)


SCN2B
GDB: 118871



AF019498


SCN3A
GDB: 132151
2q24-31
vg type III, α-subunit (280 kDa)
Brain



S69887


SCN4A
GDB: 125181
17q23.1-25.3
SkM1, vg type IV α-subunit (260 kDa),
Skeletal muscle



L04216-L04236

hyperkalemic periodic





paralysis, paramyotonia congentia,





potassturn-aggravated myotonia


SCN4B
GDB: 125182
3q21
vg type IV, β-subunit,
Heart, fetal skeletal


SCN5A
GDB: 132152

SkM2, hH1, vg type V, α-subunit,
muscle





long Q-T syndrome 3


SCN6A
GDB: 132153
2q21-23
Hs99945, vg type VI, α-subunit
Heart, uterus, fetal and






denervated skeletal






muscle


SCN7A
GDB: 228137
12q13
vg type VII, α-subunit
Brain, spinal cord


SCN8A
GDB: 631695

vg type VIII, α-subunit, motor





end-plate disease + ataxia in mice


SCN9A
GDB: 3750013

vg type IX, α-subunit
Thyroid and adrenal





neuroendocrine type
gland


SCN10A
GDB: 750014
1pter-p36.3
hPN3, vg type X
Sensory neurons, dorsal






root ganglia


SCNN1A
GDB: 366596
12pt3
SCNN1, nvg type 1 α-subunit of
Kidney, lung colon



Z92978

ENaC


SCNN1B
GDB: 434471
16p12.2-p12.1
nvg 1 β-subunit, Liddle's syndrome,
Kidney, lung colon





pseudohypoaldosterontsm I


SCNN1D
GDB: 6053678
1p36.3-p36.2
DnaCh, nvg 1 δ-subunit
Kidney, lung, colon


SCNN1G
GDB: 568769
16p122-p12.1
nvg 1 γ-subunit, Liddle's syndrome,
Kidney, lung, colon



X87160

pseudohypoaldosterontsm I



U53835-53853





Calcium Channel Type/Disease


CACNA1A
GDB: 126432
19p13
P/Q type α1A-subunit, eqisodic ataxia
Brain (cortex, bulbus,


CACNL1A4
Z80114-Z80155,
19p13.1
2, familial hemiplegic migraine,
olfacorius,



X99697, U79666

spinocerebellar ataxia 6; tottering,
hippocarnpus,





leaner, and rolling mice
cerebellum, brain stem),






motoneurons, kidney


CACNA1B
GDB: 580689
9q34
CACNN, N-type α1A-subunit
Central, peripheral


CACNL1A5
M94172, M94173


nervous system


CACNA1C
GDB: 126094
12p13
CCHL1A1, L-type α1A-subunit
Heart, fibroblasts, lung,


CACNL1A1
L29636, L29634,
12p13.3

smooth muscle (2 splice



L29629


variants)


CACNA1D
GDB: 128872
3p14.3
CCHL1A2, L-type α1D-subunit
Brain, pancreas,


CACNL1A2

3p21.3.2?

neuroendocrine


CACNA1E
GDB: 434408
1q25-31
R-type α1C-subunit
Brain, skeletal muscle


CACNL1A6



(end plate)


CACNA1F
GDB: 6053864
Xp11.23-11.22
α1F-Subunit
Retina


CACNIAG
AF27964
17q22
T-type α1G-subunit
Brain


CACNA1S
GDB: 126431
1q31-32
L-type α1B-subunit (5% 212, 95%
Skeletal muscle (brain,


CACNL1A8
Z22672, L33798

190 kDa), malignant hyperthermia
kidney)



U30666-U30707

5, hypokalernic periodic paralysis


CACNA2
GDB: 132010
7q21-22
CACNA2, CACNA2D1, αg8-subunit
α2A; skeletal muscle,


CACNL2A
Z28613, Z28609

(175 kDa), MHS3
heart, brain, ileum; α2B;



Z28605, Z28602


brain; α2CVD; aorta



Z28699, M76559


CACNB1
GDB: 132012
17q21-22
β1-Subunit (524 aa, 54 kDa)
β1A/M; skeletal muscle


CACNLB1
GDB: 1073281


β1B/C; brain, heart,



U86952-U86961


spleen



M76560, L06111



GDB: 193328


CACNB2
GDB: 132014
10p12
MYSB, β2-subunit
β2A/B/E; brain, heart,


CACNLB2
Q08289


lung, aorta


CACNB3
GDB: 341023
12q13
β2-subunit (482 aa)
Brain, heart, lung, spleen,


CACNLB3
L27584


skeletal and smooth






muscle, aorta, trachea,






ovary, colon


CACNB4
GDB: 6028693
2q22-23
β2-subunit, lethargic mice
Brain, kidney


CACNG
GDB: 132015
17q24
γ-Subunit (222 aa, 30 kDa)
Skeletal muscle, lung


CACNLG
L07738


CACNG2


γ2-Subunit, stargazin, absence
Brain





epilepsy stargazer, waggler mice


RYR1
GDB: 120359
19q13.1
Ryanodine receptor 1, Ca release
Skeletal muscle, testis,





channel, 3 splice variants,
brain, submaxillary and





malignant hyperthermia 1, central
adrenal glands, spleen





core disease


RYR2
GDB: 125278
1pter-qter
RYR2, calcium release channel
Heart, smooth muscle




1q42.1-43


RYR3
GDB: 138451
15q14
RYR3, calcium release channel
Brain, neonatal skeletal




15q14-15

muscle, adult diaphragm





Potassium Channel Type/Disease


KCNA1
GDB: 127903
12p13
RBK1, HUK1, MBK1, AEMK,
Brain, nerve, heart,



LO2750

Kv1.1, Shaker homolog 1, Shaker,
skeletal muscle, retina,





episodic ataxia 1 (with myokymia)
pancreatic islet


KCNA1B

3q26.1
Kvβ1.1, Kvβ1.3 (splice product),





β-subunit


KCNA2
GDB: 128062
12pter-qter
HK4, Kv1.2, Shaker homolog 2
Brain, nerve, heart,



X17622


pancreatic islet


KCNA2B

1p36.3
Kvβ1.2, β-subunit


KCNA8
GDB: 128079
1p13.3
Hs.1750, MK3, HLK3, HPCN3,
Skeletal muscle,



L23499

Kv1.3, Shaker homolog 3
lymphocytes (brain,






lung, thymus, spleen)


KCNA4
GDB: 126730
11p14
Hs.89647, Hs.1854, HK1, HPCN2,
Brain, nerve, heart, fetal



M60450

Kv1.4, Shaker homolog 4
skeletal muscle,



M55514


pancreatic islet


KCNA4L
GDB: 386059
11q14
Shaker homolog type 4-like


KCNA5
GDB: 127904
12p13.3-13.2
Hs.89509, HK2, HPCNI, Kv1.5
Brain, heart, kidney, lung,



M83254
12p13
Shaker homolog 5
skeletal muscle,



M60451
12p13.33-12.31

pancreatic islet


KCNA6
GDB: 128080
12p13
HBK2, Kv1.6, Shaker homolog 6
Brain, pancreatic islet



X17622


KCNA7
GDB: 127905
19q13.3
HAK6, Kv1.7 Shaker homolog 7


KCNA8


see KCNQ1


KCNA9


see KCNQ1


KCNA10
GDB: 5885822

Shaker homolog type 10, cGMP





activated


KCNB1
GDB: 128081
20q13.2
Kv2.1, Shab homolog 1
Brain, heart, kidney,






retina, skeletal muscle


KCNB2


Kv2.2, Shab homolog 2
Brain, heart, retina


KCNC1
GDB: 128082
11p15.1
Kv3.1, Shaw homolog 1
Brain, skeletal muscle,



S56770


spleen, lymphocytes



M96747


KCNC2
GDB: 127906
19q13.3-13.4
Kv3.2, Shaw homolog 2
Brain


KCNC3
GDB: 127907
19q13.3
Kv3.3, Shaw homolog 3
Brain, liver


KCNC4
GDB: 127908
1p21
Kv3.4, HKSHIIIC, Shaw homolog 4
Brain, skeletal muscle


KCND1
GDB: 128083

Kv4.1, Shal hormolog 1
Brain


KCND2
GDB: 134771

RK5, Kv4.2, Shal homolog 2
Brain, heart, aorta


KCND3
GDB: 134772

Kv4.3, KSHIVB, Shal homolog 3


KCNE1
GDB: 127909
21q22.1-22.2
MinK, ISK, vg Isk homolog 1 (129
Kidney, submandibular





aa), long Q-T syndrome 5
gland, uterus, heart,






cochlea, retina


KCNMA1
GDB: 386031
10pter-qter
SLO, Hs.62679, α-subunit member
Fetal skeletal muscle



U09383-4
7q32.1
1, α-subunit of maxiK or BK



U02632

channel


KCNMB1
GDB: 6099615
5q34
hSLO-β, β-subunit member 1 (191
Smooth, fetal skeletal



U42600

aa), β-subunit of max1K or BK
muscle, brain





channel
(hippocampus, corpus






callosum)


KCNN1
U69883

SK(Ca)1, small-conductance Ca-
Brain, heart





activated K channel, apamin-





insensitive


KCNN2


SK(Ca)2, apamin sensitive
Brain, adrenal gland


KCNN3
Y08263
1q?
SK(Ca)3, small-conductance Ca-
Brain, heart, (human



AA285078

activated K channel, intermediate
embryonic) skeletal





apamin sensitivity
muscle, liver


KCNN4
AF022150
19q13.2
IK1, intermediate-conductance
T lymphocytes, colon,



AF022797

Ca-activated K channel, KCa4,
smooth muscles,



AF033021

SK4, Gantos channel
prostata, red blood cells,



AF000972


neurons


KCNQ1
GDB: 741244
11p15.5
KCNA9, (KV)LQT1, KQT-like
Heart, cochlea, kidney,



U40990

subfamily member 1, long Q-T
lung, placenta, colon





syndrome 1


KCNQ2
GDB: 9787229,
20q13.3
KQT-like subfamily member 2 (872
Brain



Y15065,

aa)



AF033348


KCNQ3
GDB: 9787230
8q24.22-24.3
KQT-like subfamily member 3 (825
Brain



AF033347

aa)


HERG
GDB: 407638
7q35-36
HERG, similar to ether-a-go go
Brain, heart





(eag), IKr, long Q-T syndrome 2


KCNJ1
GDB: 204206
11q24
ROMK1, Kirl.1, Hs.463,
Kidney, pancreatic islets



U65406, U12541

Bartter/hyperprostaglandin





E syndrome


KCNJ2
GDB: 278964
17pter-qter
IRK1, Kir2.1, Hs.1547
Muscle, neural tissue,



U12507


heart


KCNJ3
GDB: 278325
2q24.1
GIRK1, Kir3.1
Heart, cerebellum



U50964


KCNJ4
GDB: 374080
22q13.1
HIR, HIRK1, HIRK2, Kir2.3
Heart, skeletal muscle,



Z97056


brain


KCNJ5
GDB: 547948
11q24
CIR, KATP1, GIRK4, Kir3.4
Heart, pancreas


KCNJ6
GDB: 547949
21q22.1
KCNJ7, GIRK2, KATP2, BIR1,
Cerebellum, pancreatic



U24660

Kir3.2, ataxia, weaver mice
islet


KCNJ8
GDB: 633096
12p11.23]
Kir6.1, uKATP, ubiquitious KATP
Brain, heart, skeletal,





α-subunit
smooth muscle, others


KCNJ10
GDB: 3750203
1q22-23]
Kir1.2, Kir4.1
Glia


KCNJ11
GDB: 7009893
[11p15.1]
Kir6.2, BIR, K(ATP) α-subunit,
Pancreatic islets





hyperinsulinemic hypoglycemia


KCNJ12
GDB: 4583927
[17p11.1]
Kir2.2


KCNJ15
GDB: 6275865
[21q22.2]
Kir4.2


KCNJN1
GDB: 6108062
[ ]
Kir2.2v, subfamily inhibitor 1


SUR1
GDB: 591970
[11p15.1]
SUR(1), sulfonylurea receptor,
Pancreatic islets





K(ATP) β-subunit,





hyperinsulinemic hypoglycemia


SUR2

12p12.1]
SUR2, SUR2A, B, sulfonylurea
2A: heart, 2B: brain, liver,





receptor 2 (1545-aa), β-subunit of
skeletal, smooth muscle,





K(ATP)
urinary bladder


KCNK1
GDB: 6045446
1q42-43
DPK, TWIK1
Kidney


KCNK2

1q41
TREK1
Brain


KCNK3
GDB: 9773281
2p23
TASK
Kidney





















Therapeutic Target
Enzyme Family
Assay







Alzheimer's
CMGC
ERK2 (P42mapk)


Alzheimer's
Phospholipase
PLA2


Alzheimer's
Cyclooxygenases
COX2


Alzheimer's
CaMK
MARK1


Alzheimer's
CaMK
MARK2


Alzheimer's
AGC
PKCalpha


Alzheimer's
AGC
PKCgamma


Alzheimer's
AGC
PKCgamma


Alzheimer's
Cysteine proteases
caspase-3


Alzheimer's
Cysteine proteases
caspase-6


Alzheimer's
Aspartic proteases
BACE-1 (beta-secretase)


Alzheimer's
Aspartic proteases
cathepsin D


Alzheimer's
Aspartic proteases
cathepsin F


Alzheimer's
Metalloproteases
ACE


Alzheimer's
Metalloproteases
ACE


Alzheimer's
Metalloproteases
TACE


Alzheimer's
NO synthases
constitutive NOS (cerebellar)


Alzheimer's
Monoamine &neurotransmitter
acetylcholinesterase



synthesis & metabolism


Alzheimer's
Monoamine &neurotransmitter
COMT (catechol-O-methyl transferase)



synthesis & metabolism


Alzheimer's
Monoamine &neurotransmitter
MAO-A



synthesis & metabolism


Alzheimer's
Monoamine &neurotransmitter
MAO-B



synthesis & metabolism


Alzheimer's
Monoamine &neurotransmitter
tyrosine hydroxylase



synthesis & metabolism


Alzheimer's
Phospholipase C
PLC


Alzheimer's
Miscellaneous enzymes
xanthine oxidase/superoxide O2-scavenging


Dependence/Addiction
AGC
PKA


Dependence/Addiction
AGC
PKCalpha


Dependence/Addiction
AGC
PKCbeta 1


Dependence/Addiction
AGC
PKCbeta 2


Dependence/Addiction
AGC
PKCdelta


Dependence/Addiction
Monoamine &neurotransmitter
GABA transaminase



synthesis & metabolism


Dependence/Addiction
Cyclases
adenylyl cyclase (stimulated)


Dependence/Addiction
Phospholipase C
PLC


Dependence/Addiction
ATPase
ATPase (Na+/K+)


Inflammation/Arthritis/Allergy
RTK
EGFR kinase


Inflammation/Arthritis/Allergy
RTK
FLT-1 kinase (VEGFR1)


Inflammation/Arthritis/Allergy
RTK
KDR kinase (VEGFR2)


Inflammation/Arthritis/Allergy
CTK
Fyn kinase


Inflammation/Arthritis/Allergy
CTK
HCK


Inflammation/Arthritis/Allergy
CTK
Lck kinase


Inflammation/Arthritis/Allergy
CTK
Lyn kinase


Inflammation/Arthritis/Allergy
CTK
ZAP70 kinase


Inflammation/Arthritis/Allergy
CMGC
ERK2 (P42mapk)


Inflammation/Arthritis/Allergy
CMGC
JNK 1


Inflammation/Arthritis/Allergy
CMGC
JNK 2


Inflammation/Arthritis/Allergy
CMGC
P38alpha kinase


Inflammation/Arthritis/Allergy
Phospholipase
PLA2


Inflammation/Arthritis/Allergy
Cyclooxygenases
COX1


Inflammation/Arthritis/Allergy
Cyclooxygenases
COX2


Inflammation/Arthritis/Allergy
TXA2 synthetase
TXA2 synthetase


Inflammation/Arthritis/Allergy
CaMK
MAPKAPK2


Inflammation/Arthritis/Allergy
AGC
PKA


Inflammation/Arthritis/Allergy
Lipoxygenases
12-lipoxygenase


Inflammation/Arthritis/Allergy
Lipoxygenases
15-lipoxygenase


Inflammation/Arthritis/Allergy
Serine proteases
elastase


Inflammation/Arthritis/Allergy
Serine proteases
cathepsin G


Inflammation/Arthritis/Allergy
Serine proteases
kallikrein


Inflammation/Arthritis/Allergy
Serine proteases
tryptase


Inflammation/Arthritis/Allergy
Cysteine proteases
caspase-1


Inflammation/Arthritis/Allergy
Cysteine proteases
caspase-4


Inflammation/Arthritis/Allergy
Cysteine proteases
caspase-5


Inflammation/Arthritis/Allergy
Cysteine proteases
cathepsin B


Inflammation/Arthritis/Allergy
Cysteine proteases
cathepsin X


Inflammation/Arthritis/Allergy
Aspartic proteases
cathepsin F


Inflammation/Arthritis/Allergy
Metalloproteases
MMP-1


Inflammation/Arthritis/Allergy
Metalloproteases
MMP-2


Inflammation/Arthritis/Allergy
Metalloproteases
MMP-3


Inflammation/Arthritis/Allergy
Metalloproteases
MMP-7


Inflammation/Arthritis/Allergy
Metalloproteases
MMP-8


Inflammation/Arthritis/Allergy
Metalloproteases
MMP-9


Inflammation/Arthritis/Allergy
Metalloproteases
MMP-13


Inflammation/Arthritis/Allergy
Metalloproteases
MT1-MMP (MMP-14)


Inflammation/Arthritis/Allergy
Metalloproteases
TACE


Inflammation/Arthritis/Allergy
Phosphatases
phosphatase CD45


Inflammation/Arthritis/Allergy
Phosphodiesterases
PDE2


Inflammation/Arthritis/Allergy
Phosphodiesterases
PDE4


Inflammation/Arthritis/Allergy
Phosphodiesterases
acid sphingomyelinase


Inflammation/Arthritis/Allergy
Monoamine & neurotransmitter
HNMT (histamine N-methyltransferase)



synthesis & metabolism


Inflammation/Arthritis/Allergy
Miscellaneous enzymes
myeloperoxidase


Inflammation/Arthritis/Allergy
Miscellaneous enzymes
xanthine oxidase/superoxide O2-scavenging


Neuroprotection
RTK
TRKB


Neuroprotection
CMGC
CDK5


Neuroprotection
CMGC
DYRK1a


Neuroprotection
CMGC
ERK1


Neuroprotection
CMGC
ERK2 (P42mapk)


Neuroprotection
MCGC
JCK 3


Neuroprotection
Cyclooxygenases
COX1


Neuroprotection
Cyclooxygenases
COX2


Neuroprotection
CaMK
CaMK2alpha


Neuroprotection
AGC
PKA


Neuroprotection
Cysteine proteases
caspase-3


Neuroprotection
Phosphodiesterases
PDE1


Neuroprotection
Phosphodiesterases
PDE6


Neuroprotection
NO synthases
constitutive NOS (endothelial)


Neuroprotection
NO synthases
constitutive NOS (cerebellar)


Neuroprotection
Monoamine & neurotransmitter
acetylcholinesterase



syntheses & metabolism


Neuroprotection
Monoamine & neurotransmitter
COMT (catechol-O-methyl transferase)



syntheses & metabolism


Neuroprotection
Monoamine & neurotransmitter
GABA transaminase



syntheses & metabolism


Neuroprotection
Monoamine & neurotransmitter
HNMT (histamine N-methyltransferase)



syntheses & metabolism


Neuroprotection
Monoamine & neurotransmitter
MAO-A



syntheses & metabolism


Neuroprotection
Monoamine & neurotransmitter
MAO-A



syntheses & metabolism


Neuroprotection
Monoamine & neurotransmitter
PNMT (phenylethanoiamine-N-methyl



syntheses & metabolism
transferase)


Neuroprotection
Monoamine & neurotransmitter
tyrosine hydroxylase



syntheses & metabolism


Neuroprotection
Cyclases
guanylyl cyclase (basal)


Neuroprotection
Cyclases
guanylyl cyclase (stimulated)


Neuroprotection
ATPase
ATPase (Na+/K+)


Neuroprotection
Miscellaneous enzymes
xanthine oxidase/superoxide O2-scavenging


Parkinson
CMGC
JNK 1


Parkinson
Phospholipase
PLA2


Parkinson
Cyclooxygenases
COX2


Parkinson
Cysteine proteases
caspase-3


Parkinson
NO synthases
constitutive NOS (cerebellar)


Parkinson
Monoamine & neurotransmitter
acetylcholinesterase



syntheses & metabolism


Parkinson
Monoamine & neurotransmitter
COMT (catechol-O-methyl transferase



syntheses & metabolism


Parkinson
Monoamine & neurotransmitter
MAO-A



syntheses & metabolism


Parkinson
Monoamine & neurotransmitter
MAO-B



syntheses & metabolism


Cancer
RTK
Axl kinase


Cancer
RTK
c-kit kinase


Cancer
RTK
c-kit kinase


Cancer
RTK
EGFR kinase


Cancer
RTK
EphA1 kinase


Cancer
RTK
EphA3 kinase


Cancer
RTK
EphA4 kinase


Cancer
RTK
EphB2 kinase


Cancer
RTK
FGFR1 kinase


Cancer
RTK
FGFR2 kinase


Cancer
RTK
FGFR3 kinase


Cancer
RTK
FGFR4 kinase


Cancer
RTK
FLT-1 kinase (VEGFR1)


Cancer
RTK
FLT-3 kinase


Cancer
RTK
FLT-4 kinase (VEGFR3)


Cancer
RTK
Fms/CSFR kinase


Cancer
RTK
HER2/ErbB2 kinase


Cancer
RTK
HER4/ErbB4 kinase


Cancer
RTK
KDR kinase (VEGFR2)


Cancer
RTK
PDGFRalpha kinase


Cancer
RTK
PDGFRbeta kinase


Cancer
RTK
Ret kinase


Cancer
RTK
TIE2 kinase


Cancer
RTK
TRKA


Cancer
CTK
Abl kinase


Cancer
CTK
BLK


Cancer
CTK
BMX (Bk) kinase


Cancer
CTK
BRK


Cancer
CTK
BTK


Cancer
CTK
CSK


Cancer
CTK
FAK


Cancer
CTK
Fes kinase


Cancer
CTK
Fyn kinase


Cancer
CTK
JAK2


Cancer
CTK
JAK3


Cancer
CTK
Lck kinase


Cancer
CTK
PYK2


Cancer
CTK
Src kinase


Cancer
CTK
Syk


Cancer
CTK
Yes kinase


Cancer
CMGC
CDC2/CDK1 (cycB)


Cancer
CMGC
CDK2 (cycE)


Cancer
CMGC
CDK4 (cycD1)


Cancer
CMGC
CDK5


Cancer
CMGC
CK2 (casein kinase 2)


Cancer
CMGC
DYRKla


Cancer
CMGC
ERK1


Cancer
CMGC
ERK2 (P42mapk)


Cancer
CMGC
HIPK2


Cancer
CMGC
IKKalpha


Cancer
CMGC
IKKbeta


Cancer
CMGC
JNK 1


Cancer
CMGC
JNK 2


Cancer
CMGC
NEK1


Cancer
CMGC
NEK2


Cancer
CMGC
NEK4


Cancer
CMGC
p38alpha kinase


Cancer
CMGC
p38beta 2 kinase (SAPK2b2)


Cancer
CMGC
p38delta kinase


Cancer
CMGC
p38ganuna kinase


Cancer
Cyclooxygenases
COX2


Cancer
CaMK
CaMK1delta


Cancer
CaMK
CaMK


Cancer
CaMK
CHK1


Cancer
CaMK
CHK2


Cancer
CaMK
DAPK1


Cancer
CaMK
DAPK2


Cancer
CaMK
MAPKAPK2


Cancer
CaMK
MAPKAPK3


Cancer
CaMK
MAPKAPK5 (PRAK0


Cancer
CaMK
MAARK1


Cancer
CaMK
MARK2


Cancer
CaMK
MARK4


Cancer
CaMK
Pim 1 kinase


Cancer
CaMK
Pirn2 kinase


Cancer
AGC
Akt1/PKBalpha


Cancer
AGC
Akt2/PKBbeta


Cancer
AGC
Akt3/PKBgamma


Cancer
AGC
AurA/Aur2 kinase


Cancer
AGC
AurB/Aur1 kinase


Cancer
AGC
AurC/Aur3 kinase


Cancer
AGC
P70S6Ke


Cancer
AGC
PDK1


Cancer
AGC
PKA


Cancer
AGC
PKCalpha


Cancer
AGC
PKCbeta 1


Cancer
AGC
PKCbeta 2


Cancer
AGC
PKCdelta


Cancer
AGC
PKCgamma


Cancer
AGC
PKG2


Cancer
AGC
ROCK1


Cancer
AGC
ROCK2


Cancer
AGC
RSK2


Cancer
AGC
SGK1


Cancer
Lipoxygenases
12-lipoxygenase


Cancer
TKL
RAF-1 kinase


Cancer
STE
MEK1/MAP2K1


Cancer
STE
MKK4/JNK1


Cancer
STE
MKK6


Cancer
STE
PAK1


Cancer
STE
PAK2


Cancer
Serine proteases
elastase


Cancer
Serine proteases
cathepsin G


Cancer
Cysteine proteases
caspase-2


Cancer
Cysteine proteases
caspase-3


Cancer
Cysteine proteases
caspase-8


Cancer
Cysteine proteases
caspase-9


Cancer
Cysteine proteases
cathepin B


Cancer
Cysteine proteases
cathepsin H


Cancer
Cysteine proteases
cathepsin L


Cancer
Cysteine proteases
cathepsin X


Cancer
Aspartic proteases
cathepsin D


Cancer
Aspartic proteases
cathepsin E


Cancer
Metalloproteases
MMP-1


Cancer
Metalloproteases
MMP-2


Cancer
Metalloproteases
MMP-3


Cancer
Metalloproteases
MMP-7


Cancer
Metalloproteases
MMP-8


Cancer
Metalloproteases
MMP-9


Cancer
Metalloproteases
MMP-12


Cancer
Metalloproteases
MMP-13


Cancer
Metalloproteases
MT1-MMP (MMP-14)


Cancer
Metalloproteases
TACE


Cancer'
Metalloproteases
MMP-1


Cancer
Phosphatases
phosphatase 1B


Cancer
Phosphatases
phosphatase 2B


Cancer
Phosphodiesterases
PDE2


Cancer
Phosphodiesterases
PDE4


Cancer
Phosphodiesterases
PDE5


Cancer
Phosphodiesterases
acid spingomyelinase


Cancer
NO synthases
constitutive NOS (endothelial)


Cancer
NO synthases
constitutive NOS (cerebellar)


Cancer
Cyclases
adenylyl cyclase (basal)


Cancer
Cyclases
adenylyl cyclase (stimulated)


Cancer
Phospholipase C
PLC


Cancer
Miscellaneous enzymes
myeloperoxidase


Cancer
Miscellaneous enzymes
xanthine oxidase/superoxide O2-scavenging


Diabetes
RTK
Ax1 kinase


Diabetes
RTK
EGFR kinase


Diabetes
RTK
IGFIR kinase


Diabetes
CMGC
ERK2 (P42mapk)


Diabetes
CMGC
Jnk1


Diabetes
Cyclooxygenases
COX2


Diabetes
TXA2 synthetase
TXA2 synthetase


Diabetes
CaMK
AMPKalpha


Diabetes
AGC
Akt1/PKBalpha


Diabetes
AGC
Akt2/PKBbeta


Diabetes
AGC
Akt3/PKBgamma


Diabetes
AGC
PDK1


Diabetes
AGC
PKA


Diabetes
AGC
PKCalpha


Diabetes
AGC
PKCbeta 1


Diabetes
AGC
PKCbeta 2


Diabetes
AGC
PKCgamma


Diabetes
AGC
SGK2


Diabetes
Metalloproteases
ACE


Diabetes
Metalloproteases
MMP-1


Diabetes
Metalloproteases
MMP-2


Diabetes
Metalloproteases
MMP-3


Diabetes
Metalloproteases
MMP-7


Diabetes
Metalloproteases
MMP-8


Diabetes
Metalloproteases
MMP-9


Diabetes
Metalloproteases
MT1-MMP (MMP-14)


Diabetes
Metalloproteases
TACE


Diabetes
Phosphodiesterases
PDE3


Diabetes
Phosphodiesterases
PDE4


Diabetes
Phosphodiesterases
PDE5


Diabetes
NO synthases
constitutive NOS (endothelial)


Diabetes
Monoamine & neurotransmitter
acetylcholinesterase



synthesis & metabolism


Diabetes
Monoamine & neurotransmitter
GABA transaminase



synthesis & metabolism


Diabetes
Monoamine & neurotransmitter
MAO-B



synthesis & metabolism


Diabetes
Cyclases
adenylyl cyclase (basal)


Diabetes
Miscellaneous enzymes
acetylCoA synthetase


Diabetes
Miscellaneous enzymes
HMG-CoA reductase


Diabetes
Miscellaneous enzymes
xanthine oxidase/superoxide O2-scavenging


Metabolic Diseases
Cyclooxygenases
COX2


Metabolic Diseases
AGC
PKA


Metabolic Diseases
Metalloproteases
ACE


Metabolic Diseases
Phosphodiesterases
PDE3


Metabolic Diseases
Phosphodiesterases
PDE4


Metabolic Diseases
NO synthases
constitutive NOS (endothelial)


Metabolic Diseases
Miscellaneous enzymes
acetylCoA synthetase


Metabolic Diseases
Miscellaneous enzymes
HMG-CoA reductase


Metabolic Diseases
Miscellaneous enzymes
xanthine oxidase/superoxide 02-scavenging


Obesity
CTK
PYK2


Obesity
CMGC
JNK1


Obesity
CaMK
AMPJakoga


Obesity
AGC
PKA


Obesity
Metalloproteases
ACE


Obesity
Metalloproteases
ACE


Obesity
Phosphatases
phosphatase 1B


Obesity
Phosphodiesterases
PDE2


Obesity
Phosphodiesterases
PDE3


Obesity
Monoamine & neurotransmitter
acetylcholinesterase



synthesis & metabolism


Obesity
ATPase
ATPase (Na+/K+)


Obesity
Miscellaneous enzymes
HMG-CoA reductase


Reproduction
Phospholipase
PLA2


Reproduction
Cyclooxygenases
COX1


Reproduction
Cyclooxygenases
COX2


Reproduction
Phosphodiesterases
PDE5


Reproduction
NO synthases
constitutive NOS (endothelial)


Reproduction
Cyclases
guanylyl cyclase (stimulated)


Cystic Fibrosis
Phospholipase
PLA2


Cystic Fibrosis
TXA2 synthetase
TXA2 synthetase


Cystic Fibrosis
AGC
PKA


Cystic Fibrosis
AGC
PKCbeta 1


Cystic Fibrosis
AGC
PKCbeta 2


Cystic Fibrosis
Serine proteases
elastase


Cystic Fibrosis
Serine proteases
cathepsin G


Cystic Fibrosis
Metalloproteases
MMP-2


Cystic Fibrosis
Phosphodiesterases
PDE3


Cystic Fibrosis
Phosphodiesterases
PDE5


Cystic Fibrosis
Cyclases
adenylyl cyclase (stimulated)


Cystic Fibrosis
Phospholipase C
PLC


Cystic Fibrosis
Miscellaneous enzymes
myeloperoxidase


Immunosuppression Profile
RTK
EGFR kinase


Immunosuppression Profile
CTK
JAK3


Immunosuppression Profile
CMGC
ERK2 (P42mapk)


Immunosuppression Profile
Cyclooxygenases
COX1


Immunosuppression Profile
Cyclooxygenases
COX2


Immunosuppression Profile
Serine proteases
elastase


Immunosuppression Profile
Serine proteases
cathepsin G


Immunosuppression Profile
Serine proteases
tryptase


Immunosuppression Profile
Cysteine proteases
cathepsin B


Immunosuppression Profile
Metalloproteases
ECE-1


Immunosuppression Profile
Metalloproteases
ECE-1


Immunosuppression Profile
Metalloproteases
MMP-1


Immunosuppression Profile
Metalloproteases
MMP-2


Immunosuppression Profile
Metalloproteases
MMP-9


Immunosuppression Profile
Phosphatases
phosphatase CD45


Immunosuppression Profile
Phosphodiesterases
PDE4


Immunosuppression Profile
Phosphodiesterases
acid spingomyelinase


Immunosuppression Profile
Cyclases
adenylyl cyclase (basal)


Immunosuppression Profile
Cyclases
adenylyl cyclase (stimulated)


Migraine
Cyclooxygenases
COX2


Migraine
NO synthases
constitutive NOS (cerebellar)


Migraine
Monoamine & neurotransmitter
GABA transaminase



synthesis & metabolism


Migraine
Cyclases
guanylyl cyclase (stimulated)


Pain
CMGC
ERK2 (42mapk)


Pain
Phospholipase
PLA2


Pain
Cyclooxygenases
COX1


Pain
Cyclooxygenases
COX2


Pain
AGC
PKA


Pain
Serine proteases
elastase


Pain
Metalloproteases
MMP-1


Pain
Metalloproteases
MMP-2


Pain
Metalloproteases
MMP-3


Pain
Metalloproteases
MMP-7


Pain
Phosphodiesterases
PDE4


Pain
NO synthases
constitutive NOS (endothelial)


Pain
NO synthases
constitutive NOS (cerebellar)


Pain
Monoamine & neurotransmitter
GABA transaminase



synthesis & metabolism


Pain
Monoamine & neurotransmitter
MAO-A



synthesis & metabolism


Pain
Monoamine & neurotransmitter
MAO-B



synthesis & metabolism


Pain
Monoamine & neurotransmitter
tyrosine hydroxylase



synthesis & metabolism


Pain
Miscellaneous enzymes
xanthine oxidase/superoxide 02-scavenging









Thus, according to various features, the systems, methods and devices of the invention provide, without limitation, a novel approach for using optodes and cells for measurement, including drug discovery and the monitoring of enzymatic reactions; the coating of an ion-selective PVC cocktail with TEFLON to prevent salt interference; an approach for using the optodes for extracellular measurement in a 96-well plate format, and for HERG and ammonia screening. The invention also provides a microdevice for combining optodes with cell measurements, sensor inserts for a well plate (such as PVC-coated glass disks), and bio-compatible coatings for optodes. Commercial applications for the invention include, without limitation, drug discovery, clinical monitoring, toxicity studies, chemical and biological detection, and the like.


Additional applications and protocols for analyzing ion-channel activity are described in U.S. Pat. No. 6,969,449, the entirety of which is incorporated by reference. Such protocols can be readily adapted for use with the optical ion sensors and cell assay systems described herein.


It will therefore be seen that the foregoing represents a highly advantageous approach to measurements using optical biosensor arrays. The terms and expressions employed herein are used as terms of description and not of limitation and there is no intention, in the use of such terms and expressions, of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

Claims
  • 1. A method for measuring a chemical reaction occurring within a living cell, the method comprising: (a) introducing at least one sensor into the cell without compromising the viability of the cell, the at least one sensor producing an observable signal indicating a value of a parameter associated with the reaction; wherein the at least one sensor is a nanosphere containing a PEG-lipid coating; and(b) using the signal to ascertain the parameter value.
  • 2. The method of claim 1 wherein the parameter value corresponds to the concentration of a product of the reaction.
  • 3. The method of claim 1 further comprising the step of stimulating the cell so as to affect the reaction.
  • 4. The method of claim 3 wherein the cell is stimulated by at least one of a compound, a pathogen, a pharmaceutical compound, or a potential toxin.
  • 5. The method of claim 1 further comprising the step of placing at least one sensor in proximity to the cell.
  • 6. The method of claim 5 wherein the at least one proximate sensor is covalently attached to the exterior membrane of the cell.
  • 7. The method of claim 5 wherein the at least one proximate sensor is attached to the cell membrane proximate to an ion channel of the cell.
  • 8. The method of claim 7 wherein the at least one proximate sensor is attached to the cell membrane via an antibody specific to the ion channel.
  • 9. The method of claim 1 wherein the at least one sensor comprises an ion-selective optode.
  • 10. The method of claim 9 wherein the reaction produces an ionic product.
  • 11. The method of claim 9 wherein the reaction produces a non-ionic product, and further comprising the step of ionizing the product to facilitate monitoring using the optode.
  • 12. The method of claim 9 wherein (i) the optode comprises an ion-selective ionophore, a source of triggering ions, and a signaling agent responsive to the triggering ions, (ii) the ionphore is selective for the ionic reaction product, and (iii) upon binding of a reaction-product ion, a triggering ion is released to interact with the signaling agent and thereby produce the signal.
  • 13. The method of claim 12 wherein the signal has a strength indicative of the concentration of the triggering ion, which is itself indicative of the concentration of the ionic reaction product.
  • 14. The method of claim 1 wherein monitoring the signal comprises observing the optical activity of the at least one sensor.
  • 15. The method of claim 14 wherein the signal comprises fluorescence.
  • 16. The method of claim 15 wherein monitoring the response comprises observing the optical activity of the at least one sensor using a fluorometer.
  • 17. The method of claim 10 wherein a first of the sensors and a second of the sensors each respond to different ions.
  • 18. A method for measuring a chemical reaction occurring within a living cell, the method comprising: (a) attaching at least one sensor to the exterior membrane of the cell without compromising the viability of the cell or significantly affecting the chemical reaction being monitored, the sensor producing an observable signal indicating a value of a parameter associated with the reaction; and(b) using the signal to ascertain the parameter value.
  • 19. The method of claim 18 wherein the parameter value corresponds to the concentration of a product of the reaction.
  • 20. The method of claim 18 further comprising the step of stimulating the cell so as to affect the reaction.
  • 21. The method of claim 18 wherein the cell is stimulated by at least one of a compound, a pathogen, a pharmaceutical compound, or a potential toxin.
  • 22. The method of claim 18 wherein the at least one sensor is attached to the cell membrane proximate to an ion channel of the cell.
  • 23. The method of claim 22 wherein the at least one sensor is attached to the cell membrane via an antibody specific to the ion channel.
  • 24. The method of claim 18 wherein the at least one sensor comprises an ion-selective optode.
  • 25. The method of claim 24 wherein the reaction produces an ionic product.
  • 26. The method of claim 24 wherein the reaction produces a non-ionic product, and further comprising the step of ionizing the product to facilitate monitoring using the optode.
  • 27. The method of claim 24 wherein (i) the optode comprises an ion-selective ionophore, a source of triggering ions, and a signaling agent responsive to the triggering ions, (ii) the ionphore is selective for the ionic reaction product, and (iii) upon binding of a reaction-product ion, a triggering ion is released to interact with the signaling agent and thereby produce the signal.
  • 28. The method of claim 27 wherein the signal has a strength indicative of the concentration of the triggering ion, which is itself indicative of the concentration of the ionic reaction product.
  • 29. The method of claim 18 wherein monitoring the signal comprises observing the optical activity of the at least one sensor.
  • 30. The method of claim 29 wherein the signal comprises fluorescence.
  • 31. The method of claim 30 wherein monitoring the response comprises observing the optical activity of the at least one sensor using a fluorometer.
  • 32. The method of claim 18 wherein a first of the sensors and a second of the sensors each respond to different ions.
  • 33. The method of claim 18 further comprising the step of introducing at least one internal sensor into the cell without compromising the viability of the cell, the at least one sensor emitting an observable signal indicating a value of a parameter associated with the reaction.
  • 34-44. (canceled)
  • 45. The method of claim 18, wherein the at least one sensor is a nanosphere containing a PEG-lipid coating.
  • 46. The method of claim 1, wherein the least one sensor comprises an ionophore, a chromoionophore, a polymer, and an additive.
  • 47. The method of claim 46, wherein the ionophore is Potassium Ionophore III, Sodium Ionophore IV, Sodium Ionophore V, Sodium Ionophore VI, Calcium Ionophore III, or Calcium Ionophore IV.
  • 48. The method of claim 46, wherein the chromoionophore is Chromoionophore II or Chromoionophore III.
  • 49. The method of claim 46, wherein the polymer is polyvinyl chloride.
  • 50. The method of claim 46, wherein the least one sensor further comprises a plasticizer.
  • 51. The method of claim 50, wherein the plasticizer is dioctyl sebacate.
  • 52. The method of claim 1, wherein the at least one sensor comprises an ionophore, a chromoionophore, polyvinyl chloride, dioctyl sebacate, and an additive.
  • 53. The method of claim 52, wherein the chromoionophore is Chromoionophore III.
  • 54. The method of claim 1, wherein the PEG-lipid is DSPE-PEG 500 or DSPE-PEG (2000) Folate.
  • 55. The method of claim 46, wherein the PEG-lipid is DSPE-PEG 500 or DSPE-PEG (2000) Folate.
CROSS-REFERENCE TO RELATED CASES

This application claims the benefit of U.S. Provisional Patent Application No. 60/718,255, entitled “Optical Biosensor Array and Related Systems, Methods and Devices,” filed on Sep. 16, 2005, the entire disclosure of which is hereby incorporated by reference as if set forth herein in its entirety.

Provisional Applications (1)
Number Date Country
60718255 Sep 2005 US